Sign up USA
Proactive Investors - Run By Investors For Investors

Sarepta soars on positive results from early-stage DMD clinical trial

The phase I/II study of Golodirsen hit all of its primary and secondary endpoints, with patients seeing a significant rise in dystrophin which is vital for muscle function
young boy
Duchenne muscular dystrophy is a rare muscle wasting disease that predominantly affects young boys

Shares in Sarepta Therapeutics Inc (NASDAQ:SRPT) surged in pre-market trade on Wednesday after the drug developer reported successful results from an early stage trial of its Duchenne muscular dystrophy treatment.

Sarepta said the phase I/II study of Golodirsen met all primary and secondary endpoints.

DMD is a rare progressive disease muscle disease found only in young boys who lack the protein dystrophin which is critical to muscle function.

All of the 25 boys who took part in the European trial responded to the treatment which Sarepta said demonstrated “proof of mechanism”.

On average, the levels of dystrophin in each patient increased almost eleven-fold from baseline.

Sarepta already has a drug that received accelerated approval from the FDA last year and is approved for treatment in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping.

That accounts for around 13% of the DMD market. Golodirsen is testing patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping, which accounts for around 8% of patients.

“This is now the second exon-skipping agent to have shown a statistically significant increase in dystrophin production, validating the exon-skipping approach to treating DMD boys with amenable mutations,” said principal investigator Francesco Muntoni.

Sarepta shares added 14.3% tin pre-market trading to US$46.94. In the regular session they added over 14% to $46.93 each.

View full SRPT profile View Profile

Sarepta Therapeutics Timeline

Related Articles

ventripoint_device.png
June 21 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart
pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
stem cell
June 12 2017
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use